FibroBiologics faces Nasdaq delisting after bid price stays below $1

• FibroBiologics received a Nasdaq staff determination on July 22, 2026, citing noncompliance with the $1 minimum bid price rule.
• Shares closed below $1 for 30 consecutive sessions from June 8, 2026 through July 21, 2026, triggering a delisting decision.
• Nasdaq denied the usual 180-day cure period because the company completed a reverse stock split within the past year.
• Delisting is set for July 31, 2026 unless an appeal is filed by July 29, 2026; a timely hearing request stays the suspension.
• The company plans to appeal and present a plan to regain compliance, though continued listing is not assured.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-316067), on July 24, 2026, and is solely responsible for the information contained therein.